5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.87▼ | 0.87▼ | 0.88▼ | 0.88▼ | 0.86▲ |
MA10 | 0.88▼ | 0.89▼ | 0.89▼ | 0.86▲ | 0.85▲ |
MA20 | 0.89▼ | 0.87▼ | 0.85▼ | 0.86▲ | 0.85▲ |
MA50 | 0.85▲ | 0.85▲ | 0.86▼ | 0.88▼ | 1.18▼ |
MA100 | 0.86▼ | 0.86▼ | 0.86▼ | 0.85▲ | 2.57▼ |
MA200 | 0.86▼ | 0.85▲ | 0.88▼ | 0.93▼ | 4.88▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.008▼ | -0.003▼ | -0.001▼ | 0.008▲ | 0.050▲ |
RSI | 45.719▼ | 48.061▼ | 48.157▼ | 51.236▲ | 44.156▼ |
STOCH | 11.871▼ | 23.869 | 43.441 | 62.806 | 20.934 |
WILL %R | -82.309▼ | -82.309▼ | -47.194 | -52.000 | -75.758▼ |
CCI | -136.090▼ | -140.280▼ | -74.239 | 62.621 | -33.041 |
Thursday, August 14, 2025 04:11 AM
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial ...
|
Tuesday, August 12, 2025 10:50 PM
Prologis, Inc. (NYSE:PLD) is one of the 12 Best REIT Stocks to Buy Right Now. The company reported strong growth across key financial metrics, with healthy organic expansion and a positive outlook for ...
|
Monday, August 11, 2025 04:56 AM
NasdaqGS:PRLD 1 Year Share Price vs Fair Value Explore Prelude Therapeutics's Fair Values from the Community and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 0.93 | 0.93 | 0.8221 | 0.87 | 80,871 |
14/08/25 | 0.907 | 0.961 | 0.82 | 0.945 | 221,451 |
13/08/25 | 0.8129 | 0.9174 | 0.8129 | 0.907 | 138,180 |
12/08/25 | 0.82 | 0.85 | 0.75 | 0.838 | 191,705 |
11/08/25 | 0.89 | 0.89 | 0.81 | 0.827 | 97,649 |
08/08/25 | 0.843 | 0.884 | 0.8325 | 0.8575 | 60,874 |
07/08/25 | 0.9075 | 0.91 | 0.838 | 0.857 | 161,942 |
06/08/25 | 0.845 | 0.8689 | 0.82 | 0.8498 | 107,882 |
05/08/25 | 0.87 | 0.8883 | 0.826 | 0.8413 | 37,936 |
04/08/25 | 0.84 | 0.893 | 0.82 | 0.8458 | 69,841 |
|
|
||||
|
|
||||
|
|